A PHASE I/II, MULTICENTER, OPEN-LABEL, NONCOMPARATIVE AIDS CLINCAL TRIALS

I/II 期、多中心、开放标签、非比较艾滋病临床试验

• 批准号: 8167132
• 负责人: Jaime Gerardo Deville
• 金额: $ 0.15万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167132
• 关键词: Adolescent; Child; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Phase; Research; Research Personnel; Resources; Safety; Source; Staging; United States National Institutes of Health; age group; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In stage I, to evaluate the short term safety and tolerability of raltegravir added to an initial stable background therapy which will then be optimized in children and adolescents in the age groups of ???weeks to <6 months, ?? months to <2 years, ?2 to <12 years, and ?12 to <19 years.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 在第一阶段，为了评估拉替拉韦添加到初始稳定背景治疗中的短期安全性和耐受性，然后在“周至<6个月”年龄组的儿童和青少年中进行优化。个月至 <2 年，2 至 <12 年，以及 12 至 <19 岁。